myocardial infarction/hypoxia

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention generally relates to methods of diagnosing and treating inflammation, particularly inflamed atherosclerotic plaque at risk of rupture or thrombosis. More particularly, the methods of the invention pertain to the simultaneous

BACKGROUND OF THE INVENTION Cardiovascular diseases are a leading cause of death resulting in almost 40% of deaths annually in the United States. Inadequate human myocardial regeneration poses a significant public health problem. It is estimated that 13 million Americans have coronary artery

FIELD OF THE INVENTION This invention relates to the field of medical treatment methods, including intravenous methods of administration of drugs to a subject. BACKGROUND Glyburide (also known as, e.g., glibenclamide) is a sulfonylurea drug used in treating diabetes. The systematic name of glyburide

FIELD OF THE INVENTION This invention relates to the field of medical treatment methods, including intravenous methods of administration of drugs to a subject. BACKGROUND Glyburide (also known as, e.g., glibenclamide) is a sulfonylurea drug used in treating diabetes. The systematic name of glyburide

FIELD OF THE INVENTION This invention relates to the field of medical treatment methods, including intravenous methods of administration of drugs to a subject. BACKGROUND Glyburide (also known as, e.g., glibenclamide) is a sulfonylurea drug used in treating diabetes. The systematic name of glyburide

TECHNICAL FIELD Provided are novel prodrug salts of selective aquaporin inhibitors, e.g., of aquaporin-4 and/or aquaporin-2, of Formula I as described below, their use as pharmaceuticals and pharmaceutical compositions comprising them, and novel intermediates used in and novel processes for their

TECHNICAL FIELD Provided are novel prodrug salts of selective aquaporin inhibitors, e.g., of aquaporin-4 and/or aquaporin-2, of Formula I as described below, their use as pharmaceuticals and pharmaceutical compositions comprising them, and novel intermediates used in and novel processes for their

BACKGROUND OF THE INVENTION Field of the Invention The invention generally relates to agents with hypoxic properties for treating disease. In particular, the invention provides azolylacryloyl derivatives with hypoxic properties that are suitable for treating sickle cell disease, and

FIELD OF THE INVENTION The present invention relates to methods of identifying whether a candidate compound is a modulator of an orphan G protein-coupled receptor (GPCR). Preferably the GPCR is human. In some embodiments, the GPCR is expressed endogenously by cardiomyocytes. In some embodiments, the

TECHNICAL FIELD This invention relates to the treatment of respiratory, cardiac and blood disorders by delivery into the lungs of compound comprising NO. BACKGROUND OF THE INVENTION Inhaled NO is used to treat elevated pulmonary pressures and pulmonary disorders associated with hypoxemia. This

TECHNICAL FIELD This invention relates to the treatment of respiratory, cardiac and blood disorders by delivery into the lungs of compound comprising NO substitute. BACKGROUND OF THE INVENTION Inhaled NO is used to treat elevated pulmonary pressures and pulmonary disorders associated with hypoxemia.

FIELD OF THE INVENTION This invention relates to the use of inhibitors of the renin-angiotensin system. BACKGROUND OF THE INVENTION Wasting diseases may be categorised into generalised and localised wasting diseases. To deal first with generalised wasting, many disease processes can lead to

FIELD OF THE INVENTION This invention relates to the use of inhibitors of the renin-angiotensin system. BACKGROUND OF THE INVENTION Wasting diseases may be categorised into generalised and localised wasting diseases. To deal first with generalised wasting, many disease processes can lead to

FIELD OF THE INVENTION This invention relates to the use of inhibitors of the renin-angiotensin system. BACKGROUND OF THE INVENTION Wasting diseases may be categorised into generalised and localised wasting diseases. To deal first with generalised wasting, many disease processes can lead to

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a method for preventing and/or treating osteoporosis and other disease states in animal subjects, utilizing organic boron compounds. 2. Description of the Related Art The adult skeleton is composed of 80% cortical